# Rani Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rani-therapeutics

- Industry: Biotechnology
- Headquarters: San Jose, US
- Website: www.ranitherapeutics.com
- Total disclosed funding: $90M
- Latest round: Series D (Sep 9, 2017)
- Investors on record: 10

## About

Based in California, US, Rani Therapeutics, LLC was founded in 2012 by founder Mir Imran. The company as of December 2020 has raised a total of 7 funding rounds. Rani Therapeutics' strategy and technology were created at InCube Labs, a multidisciplinary R&D center focused on generating medical advances. In April 2021, Rani Therapeutics filed to become a public company.

The company developed a "RaniPill capsule" that can be used to treat diabetes, rheumatoid arthritis, psoriasis, plaque psoriasis, and ankylosing spondylitis, providing patients with an alternative to painful and cumbersome medication injection methods.

The company plans to be listed on the Nasdaq under the symbol RANI.

## Funding rounds

- Series D, Sep 9, 2017, $39M — Novartis Venture Fund, AstraZeneca, GV
- Series C, May 26, 2015, $37M — Novartis Venture Fund, InCube Ventures, GV, VentureHealth, Pacific Venture Fund, Stevanato Group S.p.A., Western Life Sciences Venture Fund, Pinemount Investments Inc., Crystal Horizon Investments Group
- Series B, Jul 28, 2013, $9.4M — InCube Ventures, GV, VentureHealth
- Series A, Jun 13, 2012, $4M — InCube Ventures

## Investors

- InCube Ventures — Series A, Series B, Series C
- GV (https://capitalatlas.ai/funds/gv) — Series B, Series C, Series D
- VentureHealth — Series B, Series C
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series C, Series D
- Pacific Venture Fund — Series C
- Stevanato Group S.p.A. — Series C
- Western Life Sciences Venture Fund (https://capitalatlas.ai/funds/western-life-sciences-venture-fund) — Series C
- Pinemount Investments Inc. — Series C
- Crystal Horizon Investments Group — Series C
- AstraZeneca — Series D